DK0986644T3 - Preparation of erythropoietin by endogenous gene activation with viral promoters - Google Patents

Preparation of erythropoietin by endogenous gene activation with viral promoters

Info

Publication number
DK0986644T3
DK0986644T3 DK98941401T DK98941401T DK0986644T3 DK 0986644 T3 DK0986644 T3 DK 0986644T3 DK 98941401 T DK98941401 T DK 98941401T DK 98941401 T DK98941401 T DK 98941401T DK 0986644 T3 DK0986644 T3 DK 0986644T3
Authority
DK
Denmark
Prior art keywords
epo
erythropoietin
human
preparation
endogenous gene
Prior art date
Application number
DK98941401T
Other languages
Danish (da)
Inventor
Anne Stern
Michael Brandt
Konrad Honold
Hans Koll
Johannes Auer
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0986644(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1997153681 external-priority patent/DE19753681A1/en
Priority claimed from US09/113,692 external-priority patent/US6548296B1/en
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Application granted granted Critical
Publication of DK0986644T3 publication Critical patent/DK0986644T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Abstract

The invention concerns human cells which, owing to the activation of the endogenous human erythropoietin gene, can produce erythropoietin (EPO) in sufficient quantities and degree of purity to allow human EPO to be economically produced as a pharmaceutical preparation. The invention also concerns a process for producing such human EPO-producing cells, DNA-constructs for activating the endogenous EPO gene in human cells and a process for the large-scale production of EPO in human cells.
DK98941401T 1997-07-23 1998-07-22 Preparation of erythropoietin by endogenous gene activation with viral promoters DK0986644T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97112640 1997-07-23
DE1997153681 DE19753681A1 (en) 1997-12-03 1997-12-03 Erythropoietin composition has a highly specific activity
US09/113,692 US6548296B1 (en) 1997-07-23 1998-07-10 Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
PCT/EP1998/004590 WO1999005268A1 (en) 1997-07-23 1998-07-22 Production of erythropoietin by endogenous gene activation

Publications (1)

Publication Number Publication Date
DK0986644T3 true DK0986644T3 (en) 2007-01-29

Family

ID=27217987

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98941401T DK0986644T3 (en) 1997-07-23 1998-07-22 Preparation of erythropoietin by endogenous gene activation with viral promoters

Country Status (13)

Country Link
EP (1) EP0986644B1 (en)
JP (1) JP4541539B2 (en)
CN (1) CN1151258C (en)
AT (1) ATE341625T1 (en)
AU (1) AU754619B2 (en)
BR (1) BRPI9811031B8 (en)
CA (1) CA2298015C (en)
DE (1) DE59813758D1 (en)
DK (1) DK0986644T3 (en)
ES (1) ES2273434T3 (en)
TR (1) TR200000175T2 (en)
TW (1) TW574372B (en)
WO (1) WO1999005268A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
CA2309810C (en) 1997-12-03 2014-07-08 Roche Diagnostics Gmbh Erythropoietin with high specific activity
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
AT409379B (en) 1999-06-02 2002-07-25 Baxter Ag MEDIUM FOR PROTEIN- AND SERUM-FREE CELL CULTURE
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
PT1471871E (en) 2001-02-02 2007-06-05 Ortho Mcneil Pharm Inc Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
KR100493703B1 (en) * 2001-10-30 2005-06-02 신풍제약주식회사 Recombinant Vectors Useful in Animal Cells and Expression Vectors for Preparing Erythropoietin
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
EP1461065A1 (en) 2001-11-28 2004-09-29 Ortho-McNeil Pharmaceutical, Inc. Erythropoietin dosing regimen for treating anemia
AU2002351444B2 (en) 2001-12-07 2008-02-21 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
US7129267B2 (en) 2002-03-11 2006-10-31 Janssen Pharmaceutica N.V. Methods for SHP1 mediated neuroprotection
DK2287288T3 (en) 2002-07-09 2013-01-07 Baxter Int Medium free of animal protein for cell culture
BRPI0409895B8 (en) 2003-05-09 2021-05-25 Crucell Holland Bv method of culturing cells derived from per.c6 cells capable of growing in suspension to increase the product yield of said cells
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
ES2790887T3 (en) 2006-01-04 2020-10-29 Baxalta Inc Cell culture medium without oligopeptides
CN101062407A (en) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 Function of erythropoietin in the preventing and treating of retinal injury
US20110091474A1 (en) * 2007-03-12 2011-04-21 Kang Zhang Compositions and Methods For Diagnosing and Treating Diabetic Micro Vascular Complications
CA2712606A1 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
EP2334699B1 (en) 2008-09-23 2013-09-11 F. Hoffmann-La Roche AG Purification of erythropoietin
CN102232085A (en) 2008-09-26 2011-11-02 Ambrx公司 Modified animal erythropoietin polypeptides and their uses
CN102659928B (en) * 2010-09-17 2014-02-05 上海凯茂生物医药有限公司 Synthetic signal peptide and application thereof
CN104059128B (en) * 2010-09-17 2016-08-03 上海凯茂生物医药有限公司 The signal peptide of a kind of synthetic and application thereof
CN102659927B (en) * 2010-09-17 2014-02-05 上海凯茂生物医药有限公司 Synthetic signal peptide and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77081A (en) * 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
JPS62171696A (en) * 1986-01-23 1987-07-28 Sumitomo Chem Co Ltd Production of human erythropoietin
JPS62265992A (en) * 1986-05-12 1987-11-18 Ajinomoto Co Inc Production of valuable substance using human cell
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
JPH01165393A (en) * 1987-12-21 1989-06-29 Sumitomo Chem Co Ltd Method for purifying recombinant human erytheropoietin
SG88714A1 (en) * 1989-11-06 2002-05-21 Cell Genesys Inc Production of proteins using homologous recombination
ES2104690T3 (en) * 1989-12-22 1997-10-16 Applied Research Systems MODIFICATIONS OF THE EXPRESSION OF ENDOGENOUS GENES WITH A REGULATORY ELEMENT BY MEANS OF APPROVAL RECOMBINATION.
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
IL118201A (en) * 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof

Also Published As

Publication number Publication date
CN1151258C (en) 2004-05-26
TW574372B (en) 2004-02-01
CN1265143A (en) 2000-08-30
WO1999005268A1 (en) 1999-02-04
AU8978698A (en) 1999-02-16
AU754619B2 (en) 2002-11-21
CA2298015A1 (en) 1999-02-04
ATE341625T1 (en) 2006-10-15
EP0986644B1 (en) 2006-10-04
BRPI9811031B8 (en) 2021-07-06
DE59813758D1 (en) 2006-11-16
TR200000175T2 (en) 2001-01-22
EP0986644A1 (en) 2000-03-22
CA2298015C (en) 2015-01-27
ES2273434T3 (en) 2007-05-01
BRPI9811031B1 (en) 2011-10-04
BRPI9811031A (en) 2000-08-08
JP2001511343A (en) 2001-08-14
JP4541539B2 (en) 2010-09-08

Similar Documents

Publication Publication Date Title
DK0986644T3 (en) Preparation of erythropoietin by endogenous gene activation with viral promoters
WO2002029083A3 (en) Industrial-scale serum-free production of recombinant proteins in mammalian cells
PT1428878E (en) Process for the production and purification of erythropoietin
EP0931162A4 (en) Production of a multimeric protein by cell fusion method
CY1111099T1 (en) Yeast Executives Producing Steroids In Autonomous Way
AU2270899A (en) Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments
AU5102899A (en) Process and materials for production of glucosamine
ATE314389T1 (en) SHORTENED NEUROTROPHIC FACTOR DERIVED FROM A GLIA CELL LINE
EP0367145A3 (en) New process for the production of l-2-amino-4(hydroxymethyl-phospinyl)-butyric acid
AU7471698A (en) Intracellular production of hepatitis c e1 and e2 truncated polypeptides
DK1346026T3 (en) Microorganism producing 5'inosinic acid and process for producing 5'inosinic acid using this
DK1015494T3 (en) Process for the preparation of catalytic antibodies
NO993119L (en) Material containing poly-reaction products and process for making the same
DE69931807D1 (en) PREPARATION OF ASCORBIC ACID USING YEAST
DK1000154T3 (en) Identification of human cell lines for production of human proteins by endogenous gene activation
CA2263790A1 (en) Method for immortalizing cells
CA2191407A1 (en) Process for using the yeast adh ii promoter system for the biotechnological production of heterologous proteins in high yields
MXPA02012376A (en) Method for producing 5-aminosalicyclic acid.
ATE413451T1 (en) METHODS FOR MASS CULTIVATION OF CELLS THAT PRODUCE RECOMBINANT HUMAN ERYTHROPOIETIN
DK1019512T3 (en) Process for the preparation of branched fatty acids by genetically modified plants
DK1001929T3 (en) Process for the preparation of 3-cyano-2,4-dihalo-5-fluoro-benzoic acids
HUT50099A (en) Process for producing alkyl-esters of 4-chloro-3-alkoxy-but-2e-enic acid
WO1999051722A3 (en) Recombinant l-n-carbamoylase derived from arthrobacter aurescens, and a method for producing l-amino acids by using the same
TR200700154A2 (en) Preparation of erythropoietin by endogenous gene activation.
DE50001638D1 (en) METHOD FOR PRODUCING 4,6-DICHLORPYRIMIDINE